Innovent Biopharmaceutical Transformation
R&D: Bringing More Molecules into Late Stage with
Positive PoC Data
We achieved positive PoC readouts for 7 promising assets
Oncology
Non-oncology
IBI188
(CD47)
highly-potent CD47 mAb
IBI326
(BCMA)
Under the optimal dose regime,
preliminary efficacy data from
12 patients is ORR =83.3% and
the response will deepen as
treatment prolongs
Potentially China 1st BCMA
CAR-T Product
Impressive preliminary phase
1/2 data with rapid onset of
action
and long-lasting
efficacy, as well as favorable
safety profile
IBI310
(CTLA-4)
CTLA-4 +PD-1 combo
therapy for solid tumors
Preliminary POC signal in Phase
1b studies and progressed into
registrational trials for multiple
indications
IBI344
(ROS1/NRTK)
Next-generation potent TKI
target ROS1/NRTK fusions
ORR% 90.5% in the crizotinib-
naïve patient and ORR 43.8%
in the crizotinib-treated
patient group. Receive NMPA
BTD for ROS1+ NSCLC in
2022.02
IBI362
(GLP1/
GCGR)
Potentially the best
molecules in metabolic
Robust efficacy data with good
safety profile to deliver
multiple clinical benefits in
treating T2DM and obesity.
Plan to start Phase 3 in 2022.
IBI112
(IL-23)
BIC candidate with
long acting potential
Observed significant efficacy
signal in the Phase 2 study for
psoriasis and expandable to
other autoimmune diseases.
IBI302
(VEGF/C)
Global FIC
ophthalmology molecule
Promising visual acuity
improvement with edema
reduction observed in Phase
1b clinical study and Phase 2
ongoing 2022.
Innovent
Confidential
Copyright©2022 InnoventView entire presentation